Valutazione di un intervento per ridurre i tempi di trattamento per i pazienti con TAVI (TREAT)
Evaluation d'Une Intervention Pour Reduire le Delai de Traitement Des Patients Traites Par TAVI
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).
Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.
In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Brest, Francia
- Brest University Hospital
-
Rouen, Francia
- CHU de Rouen
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient over 18 years of age;
- Aortic stenosis
- Indication of TAVI
- Patient affiliated or benefiting from a health insurance scheme
- Patient having read and understood the information letter and having signed the consent form
Exclusion Criteria:
- TAVI indication not retained
- Patient who are not fluent in French and have no one around them to translate,
- Patient who do not have access to the Internet (at home or in their immediate environment)
- Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
- Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Nessun intervento: Control group
The randomized centres in this group will not change their practices. |
|
|
Sperimentale: Patient component
The randomized centres in this group will be required to present patients with:
|
Video, booklet, website |
|
Sperimentale: Organisational component
The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times. |
Coronarography, CT-scan, anesthesia... |
|
Sperimentale: Patient and organisational components
The randomized centres in this group will have to implement the two components. |
Video, booklet, website Coronarography, CT-scan, anesthesia... |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Lasso di tempo: Month 6
|
Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months |
Month 6
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to care, in days
Lasso di tempo: Month 6
|
The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure |
Month 6
|
|
Mortality rate
Lasso di tempo: Months 3 and 6
|
The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure |
Months 3 and 6
|
|
Patients' health-related quality of life
Lasso di tempo: Baseline, Months 3 and 6
|
Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L). |
Baseline, Months 3 and 6
|
|
Patient knowledge of the disease and the TAVI procedure
Lasso di tempo: Baseline, Month 3
|
Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score). |
Baseline, Month 3
|
|
Medication compliance
Lasso di tempo: Month 6
|
Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance). |
Month 6
|
|
Patient satisfaction
Lasso di tempo: Month 6
|
Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale |
Month 6
|
|
Number of visits to the patient section of the website
Lasso di tempo: Month 6
|
The number of visits to the website will be assessed through Googleanalytics® |
Month 6
|
|
Number of visits to the professional section of the website
Lasso di tempo: Month 6
|
The number of visits to the website will be assessed through Googleanalytics® |
Month 6
|
|
Acceptability of the intervention for participating centers
Lasso di tempo: Month 6
|
The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment. |
Month 6
|
|
Intervention components' dose and fidelity
Lasso di tempo: Month 6
|
Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol. |
Month 6
|
|
Reached populations
Lasso di tempo: Month 6
|
Percentage of target individuals who benefit from activities of each component of the intervention |
Month 6
|
|
Intervention components' adaptation
Lasso di tempo: Month 6
|
Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided. |
Month 6
|
|
Incremental cost-effectiveness ratio
Lasso di tempo: Month 6
|
The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire |
Month 6
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Helene Eltchaninoff, Pr, University Hospital, Rouen
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2021/0226/HP
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .